Phio Pharmaceuticals Corp (PHIO) Stock Price, Quote & News

Company Profile

Phio Pharmaceuticals Corp., a a clinical stage biotechnology company, engages in the development of immuno-oncology therapeutics in the United States. The company is developing PH-762, an INTASYL compound in Phase 1b dose-escalating clinical trials to reduce the expression of cell death protein 1 (PD-1), a protein that inhibits T cells' ability to kill cancer cells; and PH-762 treated double positive tumor infiltrating lymphocytes, which is in Phase 1 clinical trials to treat advanced melanoma a...

Industry: Biotechnology

Sector: Healthcare

Phone: 508 767 3861

Website: phiopharma.com

Address:

11 Apex Drive, Suite 300A PMB 2006, Marlborough, United States

Nik_CA Jan. 15 at 9:29 PM

$PHIO I would appreciate if someone could share OGs and longs who share their DD frequently on the board Please and thank you

0 · Reply

DosGatos Jan. 15 at 9:01 PM

$PHIO no buyout ahead!

0 · Reply

JohnTrack Jan. 15 at 7:34 PM

$PHIO monitoring flush and recover!

0 · Reply

JohnTrack Jan. 15 at 5:29 PM

$PHIO quick spark in headlines... https://www.rapidticker.com/news/phio-phio-pharmaceuticals-announces-participation-in-a1b9ba

0 · Reply

newsfile_corp Jan. 15 at 1:47 PM

https://nfne.ws/280343 $PHIO @PhioPharma11803 #immunooncology #INTASYL #PH762 #PHIO #siRNA #Chemicals #Pharmaceutical #Biotechnology #Healt

0 · Reply

Uncle_Tom Jan. 15 at 1:30 PM

$PHIO buyout ahead

1 · Reply

spikespants Jan. 15 at 1:28 AM

$PHIO to many bears in this thread. I own a small amount. Dont really care what they have to say. Maybe they should just keep shorting and not keep telling everyone about it. Nobody cares.

0 · Reply

DosGatos Jan. 14 at 9:20 PM

$PHIO Back to Not Accumulating!

0 · Reply

Stonkey Jan. 14 at 8:50 PM

$PHIO Oh yes, kiddo's......oooooh yes!

0 · Reply

CoffeeBender Jan. 14 at 6:54 PM

$PHIO Back to accumulating.

0 · Reply

Phio Pharmaceuticals Announces Participation in the Sidoti Micro-Cap Virtual Investor Conference January 21-22, 2026

Dec 23, 2025, 8:45 AM EST - 23 days ago

Phio Pharmaceuticals Announces Significant Step Forward in its Drug Development Program for PH-762

Nov 25, 2025, 11:30 AM EST - 7 weeks ago

Phio Pharmaceuticals Announces Completion of Enrollment in Phase 1b Clinical Trial of INTASYL siRNA Lead Compound PH-762

Nov 17, 2025, 8:45 AM EST - 2 months ago

Phio Pharmaceuticals Announces Upcoming Podium Presentation at the Advanced Therapies USA 2025 Congress

Nov 13, 2025, 4:15 PM EST - 2 months ago

Phio Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides Business Update

Nov 7, 2025, 10:30 AM EST - 2 months ago

Phio Pharmaceuticals to Present Recent Clinical Results from Skin Cancer Trial with siRNA based INTASYL PH-762

Nov 7, 2025, 7:45 AM EST - 2 months ago

Phio Pharmaceuticals Announces INTASYL PH-762 is Named Immunomodulatory Solution of the Year in the BioTech Breakthrough Award Program

Nov 3, 2025, 1:40 PM EST - 2 months ago

Phio Pharmaceuticals Announces Exercise of Warrants for Approximately $13.4 Million Gross Proceeds

Nov 3, 2025, 7:45 AM EST - 2 months ago

Phio Pharmaceuticals Announces Positive Pathology Results: Final Maximum Dose Cohort for INTASYL PH-762 Skin Cancer Trial

Oct 31, 2025, 10:15 AM EDT - 2 months ago

Phio Pharmaceuticals Announces Appointment of Mr. David H. Deming to the Position of Lead Independent Director

Oct 21, 2025, 7:45 AM EDT - 3 months ago

Phio Pharmaceuticals Announces Participation in the Renmark Financial Communications Live Virtual Non-Deal Roadshow Series

Sep 18, 2025, 7:45 AM EDT - 4 months ago

Phio Pharmaceuticals to Present at the Life Sciences Future Conference

Sep 3, 2025, 7:45 AM EDT - 4 months ago

Phio Pharmaceuticals to Present at the H.C. Wainwright 27th Annual Global Investment Conference

Aug 14, 2025, 4:15 PM EDT - 5 months ago

Phio Pharmaceuticals Reports Second Quarter 2025 Financial Results and Provides Business Update

Jul 25, 2025, 3:04 PM EDT - 6 months ago

Phio Pharmaceuticals Announces Exercise of Warrants for Approximately $2.5 Million Gross Proceeds

Jul 25, 2025, 12:36 PM EDT - 6 months ago

Phio Pharmaceuticals Announces Pathology Results for Four of Five Patients in Fourth Cohort

Jul 25, 2025, 7:45 AM EDT - 6 months ago

Phio Pharmaceuticals Announces Agreement with U.S. Manufacturing Source for Drug Substance

Jun 25, 2025, 7:45 AM EDT - 7 months ago

Phio Pharmaceuticals Announces Positive Safety Monitoring Committee Recommendation to Advance INTASYL PH-762 Skin Cancer Clinical Trial to Fifth Dose Escalation Cohort

Jun 24, 2025, 7:45 AM EDT - 7 months ago

Phio Pharmaceuticals Announces Participation in the Renmark Financial Communications Virtual Non-Deal Roadshow Series

Jun 6, 2025, 7:45 AM EDT - 7 months ago

Phio Pharmaceuticals Announces Strategic Initiative to Create Awareness of the Comprehensive INTASYL siRNA Portfolio

May 19, 2025, 7:45 AM EDT - 8 months ago

Phio Pharmaceuticals Announces Participation in the Sidoti Micro-Cap Virtual Investor Conference

May 15, 2025, 4:15 PM EDT - 8 months ago

Phio Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Business Update

May 7, 2025, 7:45 AM EDT - 9 months ago

Phio Pharmaceuticals Announces Positive Pathology Results in Third Cohort in INTASYL PH-762 Skin Cancer Clinical Trial

Apr 9, 2025, 7:45 AM EDT - 10 months ago

Phio Pharmaceuticals Announces Positive Safety Monitoring Committee Recommendation to Advance INTASYL PH-762 Skin Cancer Study to Fourth Dose Escalation Cohort

Apr 3, 2025, 7:45 AM EDT - 10 months ago

Phio Pharmaceuticals Announces Podium Presentations on INTASYL siRNA Lead Product Candidates PH-762 and PH-894

Mar 31, 2025, 4:00 PM EDT - 10 months ago

Phio Pharmaceuticals Reports 2024 Year End Financial Results and Provides Business Update

Mar 10, 2025, 7:45 AM EDT - 11 months ago

American Academy of Dermatology Awards Podium Presentation to Phio Pharmaceutical's Clinical Research at 2025 Annual Meeting

Mar 5, 2025, 7:45 AM EST - 11 months ago

Phio Pharmaceuticals Announces Completion of Enrollment in Third Safety Cohort in PH-762 Phase 1b Dose-Escalation Study

Feb 20, 2025, 7:45 AM EST - 11 months ago

Phio Pharmaceuticals Announces Appointment of David H. Deming to Board of Directors

Jan 22, 2025, 7:00 AM EST - 1 year ago

Phio Pharmaceuticals to Participate in the Renmark Financial Communications Virtual Non-Deal Roadshow Series

Jan 21, 2025, 4:15 PM EST - 1 year ago

Phio Pharmaceuticals Announces Closing of $1.83 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Jan 16, 2025, 1:00 PM EST - 1 year ago

Phio Pharmaceuticals Announces $1.83 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Jan 15, 2025, 7:00 AM EST - 1 year ago

Phio Pharmaceuticals Announces $2.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Jan 14, 2025, 7:00 AM EST - 1 year ago

Phio Pharmaceuticals Announces $3.19 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Jan 13, 2025, 12:45 PM EST - 1 year ago

Cancer-Focused Phio Pharmaceuticals Stock Gains 300% On Monday - Here's Why

Jan 13, 2025, 7:45 AM EST - 1 year ago

Phio Pharmaceuticals Announces Promising Results of Second Cohort from Its Ongoing Clinical Study of PH-762

Jan 2, 2025, 7:45 AM EST - 1 year ago

Phio Pharmaceuticals Announces Publication in Clinical, Cosmetic and Investigational Dermatology

Dec 23, 2024, 1:15 PM EST - 1 year ago

Phio Pharmaceuticals Announces Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Dec 19, 2024, 2:28 PM EST - 1 year ago

Phio Pharmaceuticals Announces $1.15 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Dec 19, 2024, 7:45 AM EST - 1 year ago

Phio Pharmaceuticals Announces Positive Safety Monitoring Committee (SMC) Recommendation to Continue to Third Dose Cohort in its Clinical Study of PH-762

Dec 12, 2024, 9:21 AM EST - 1 year ago

Phio Pharmaceuticals Announces Publication in Frontiers in Immunology

Dec 10, 2024, 7:45 AM EST - 1 year ago

Phio Pharmaceuticals is a Finalist for the Technology Disruptor of the Year Award

Nov 19, 2024, 7:45 AM EST - 1 year ago

Phio Pharmaceuticals Announces Completion of Enrollment in Second Cohort in Phase 1b Dose-Escalating Clinical Study

Nov 14, 2024, 5:47 PM EST - 1 year ago

Phio Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Business Update

Nov 7, 2024, 10:00 AM EST - 1 year ago

Phio Pharmaceuticals Announces Upcoming Presentation at the 39th Annual Meeting of the Society for Immunotherapy of Cancer (SITC)

Oct 18, 2024, 1:30 PM EDT - 1 year ago

Correction to Registration Link to Access Phio Pharmaceuticals' Presentation in the Renmark Financial Communications Virtual Non-Deal Roadshow Series

Oct 18, 2024, 8:00 AM EDT - 1 year ago

Phio Pharmaceuticals to Participate in the Renmark Financial Communications Virtual Non-deal Roadshow Series

Oct 16, 2024, 8:00 AM EDT - 1 year ago

Phio Pharmaceuticals Presenting Data on Its INSTAYL Compound PH-894 at ASGCT's 2024 Advancing Gene and Cell Therapies for Cancer Conference

Oct 7, 2024, 8:00 AM EDT - 1 year ago

Phio Announces Data Showcasing INTASYL's Role in Helping Immune Cells Target and Kill Cancer Cells

Sep 25, 2024, 8:00 AM EDT - 1 year ago

INTASYL Technology and Compounds to be Focus of Presentation at 20th Annual Meeting of Oligonucleotide Therapeutics Society

Nik_CA Jan. 15 at 9:29 PM

$PHIO I would appreciate if someone could share OGs and longs who share their DD frequently on the board Please and thank you

0 · Reply

DosGatos Jan. 15 at 9:01 PM

$PHIO no buyout ahead!

0 · Reply

JohnTrack Jan. 15 at 7:34 PM

$PHIO monitoring flush and recover!

0 · Reply

JohnTrack Jan. 15 at 5:29 PM

$PHIO quick spark in headlines... https://www.rapidticker.com/news/phio-phio-pharmaceuticals-announces-participation-in-a1b9ba

0 · Reply

newsfile_corp Jan. 15 at 1:47 PM

https://nfne.ws/280343 $PHIO @PhioPharma11803 #immunooncology #INTASYL #PH762 #PHIO #siRNA #Chemicals #Pharmaceutical #Biotechnology #Healt

0 · Reply

Uncle_Tom Jan. 15 at 1:30 PM

$PHIO buyout ahead

1 · Reply

spikespants Jan. 15 at 1:28 AM

$PHIO to many bears in this thread. I own a small amount. Dont really care what they have to say. Maybe they should just keep shorting and not keep telling everyone about it. Nobody cares.

0 · Reply

DosGatos Jan. 14 at 9:20 PM

$PHIO Back to Not Accumulating!

0 · Reply

Stonkey Jan. 14 at 8:50 PM

$PHIO Oh yes, kiddo's......oooooh yes!

0 · Reply

CoffeeBender Jan. 14 at 6:54 PM

$PHIO Back to accumulating.

0 · Reply

RetiredOldGeezer Jan. 14 at 3:21 PM

$PHIO Holidays are over - I thought Old Bob and his crew would be back at work by now - just hope he does not make anymore token buys of 5000 shares or the wait will extend even longer

1 · Reply

Stonkey Jan. 13 at 6:45 PM

$PHIO 16 cents to go guys....next REVERSE SPLIT is peeking around the corner again.....

1 · Reply

Stonkey Jan. 13 at 3:11 PM

$PHIO How is water wet? How is ice cold? How is fire hot?

0 · Reply

Stonkey Jan. 13 at 3:10 PM

$PHIO Says the loser who is down 99.9999998% on his "investment" from 12 years ago. How much do you have left, 37 cents? 🤣🤣🤣

1 · Reply

DERDER Jan. 13 at 3:02 PM

$PHIO donkey doesn’t know what scam means?. He needs to look in the mirror for the definition.

0 · Reply

PitaPierogi Jan. 13 at 2:55 PM

$PHIO how is it a scam?

0 · Reply

Stonkey Jan. 13 at 2:37 PM

$PHIO No buyout for scams.

0 · Reply

PitaPierogi Jan. 13 at 12:34 PM

$PHIO buyout.

0 · Reply

jarias115 Jan. 12 at 9:52 PM

$PHIO you keep testing the 1.2, I need you to break through

0 · Reply

bmuromoto Jan. 12 at 8:50 PM

$AUUD $IPW $SUGP $PHIO need some juice on these! Blow some luck on these…

0 · Reply

SmurfVillage Jan. 9 at 4:01 PM

$PHIO Reminder that Phio has already released strong interim data, the full pathology results for the final, highest-dose cohort (Cohort 5) are expected in Q1 2026. We are looking for consistency in "complete responses" (100% tumor clearance). Previous interim data for this cohort showed one patient with 100% clearance and another with over 90%,

0 · Reply

SuperGreenToday Jan. 9 at 2:26 PM

$PHIO

0 · Reply

Market Cap	12.06M
Revenue (ttm)	0.00
Net Income (ttm)	-7.15M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	137,000
Avg Vol	519,172
Day's Range	N/A - N/A
Shares Out	10.76M
Stochastic %K	31%
Beta	0.89
Analysts	Sell
Price Target	$14.00